Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    104
  • sponsor
    CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Updated on 30 November 2021
measurable disease
carcinoma
anticoagulants
squamous cell carcinoma
neutrophil count
adenosquamous carcinoma
aptt
adenocarcinoma
anticoagulant
immunomodulator

Summary

This study is an open, single-arm, multicenter phase II study to investigate the efficacy and safety of SG001 for relapsed or metastatic uterine cervical cancer patients with PD-L1 positive (CPS1), and has failed at least first line platinum-based chemotherapy.

Description

Phase II: open, single-arm, multicenter.

Details
Condition cervical cancer, uterine, Uterine Serous Carcinoma, Disorders of cervix NOS, Uterine Cancer, Cervical Cancer
Treatment SG001
Clinical Study IdentifierNCT04886700
SponsorCSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Last Modified on30 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

\. Age 18 on the day of signing informed consent and volunteered to participated in this study
\. Histologically documented relapsed or metastatic uterine cervical cancer including squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma, a relevant pathological report must also be provided
\. Relapsed or metastatic uterine cervical cancer patient who has failed at least first line platinum-based chemotherapy, which means having disease progression during or following at least first line platinum based chemotherapy or for which platinum based chemotherapy is not tolerated, having disease progression within 6 months of or during neoadjuvant or adjuvant treatment with platinum based chemotherapy can also be accepted
\. Programmed Cell Death Ligand 1 (PD-L1) positive expression defined by Combined Positive Score (CPS) 1
\. All the subjects should have at least one measurable lesion in CT or MRI test assessed by RECIST 1.1. A previously irradiated site lesion could only be counted as a target lesion if there was clear sign of progression since the irradiation
\. If subjects have received anti-tumor therapies before, the toxicity severity must decrease to Grade1 evaluated by NCI-CTCAE 5.0, except for residual alopecia or fatigue
\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
\. Has a predicted survival period 3 months assessed by investigators
\. Demonstrate adequate organ function as defined below
Blood routine tests (No blood transfusions were performed, no hematopoietic stimulators were used, and no drugs were used to correct blood cell counts ): Absolute neutrophil count (ANC) 1.5109/L; Platelets 75109/L; Hemoglobin (HGB)9 g/dL
Serum biochemical indexs: Serum creatinine 1.5 X ULN or Creatinine clearance (CCr) 50mL/min; Serum total bilirubin (TBIL) 1.5 X upper limit of normal ULN (Subjects with Gilbert's syndrome can be up to 3 x ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 X ULN or 5 X ULN for subjects with hepatocellular carcinoma and liver metastases
Coagulation function: Activated partial thromboplastin time (APPT) and International Normalized Ratio (INR)1.5 X ULN (No anticoagulants or other drugs affecting clotting function were used within 14 days prior to the first administration, except for subjects requiring long-term anticoagulant therapy)
\. Women of child-bearing potential (WOCBP) should be willing to use reliable contraceptive methods from signing the informed consent form to 6 months after last dose of investigational drug

Exclusion Criteria

\. History of allergic reactions attributed to any monoclonal antibody, and uncontrolled history of allergic asthma
\. Patients with other types of malignant tumours that have progressed or require treatment within 5 years prior to the screening, but well-treated skin basal cell carcinoma, skin squamous cell carcinoma, or superficial bladder cancer, and having cured carcinoma in situ, e.g. breast carcinoma in situ, can be accepted
\. Patients with any active autoimmune disease, but subjects with following diseases are allowed for further screening: subjects with well-controlled type I diabetes, well-controlled hypothyroidism with hormone replacement therapy, skin diseases (such as vitiligo, psoriasis, or hair loss) without systemic treatment, or who are not expected to relapse without external triggers
\. History of primary immunodeficiency
\. Patients with serious cardiovascular diseases, such as grade 2 or above heart failure based on the NYHA (New York Heart Association) Class guidelines, previous myocardial infarction within 3 months, poorly controlled arrhythmias or unstable angina pectoris, previous arterial or venous thrombosis events within 3 months (e.g. transient ischemic attack, cerebral hemorrhage, cerebral infarction, deep vein thrombosis and pulmonary embolism)
\. Has history of Interstitial Lung Disease (Patients caused by radiotherapy are eligible), or non-infectious pneumonitis need for glucocorticoid therapy
\. Have a history of active tuberculosis
\. Subjects with untreated or treated but still symptomatic central nervous system metastases (except for residual signs or symptoms related to CNS treatment, those with stable or improved neurological symptoms at least 2 weeks prior to screening can be included)
\. Prior therapy with any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways including anti-PD-1, anti-PD-L1, anti CTLA-4, OX40 agonist, and anti-CD137, etc
\. Immune-related adverse events of grade 3 or higherNCI-CTCAE 5.0after immune therapy
\. Have received major surgery or radical radiotherapy within 28 days, or palliative radiotherapy within 14 days, or radiological agents (strontium, samarium, etc.) within 56 days prior to screening
\. Have received systemic anti-tumour therapy 28 days before the first dose, including but not limited to chemotherapy, immunotherapy, macromolecular targeted therapy, and biological therapy (tumour vaccine, cytokines or growth factors controlling cancer); Patients who received small-molecule targeted and oral fluorouracil therapy within 14 days before the first dose
\. Have received attenuated live vaccine within 28 days before the first dose or planned to receive during the study period
\. Have received Chinese herbal medicine or Chinese patent medicine with anti-tumor activity within14 days prior to the first dose
\. Any active infection requiring systemic treatment by intravenous infusion within 28 days prior to the first dose
\. Have received systemic corticosteroids (at doses equivalent to or greater than 10 mg/day of prednisone) or other immunosuppressive drugs within 14 days prior to the first dose of study drug
\. Have participated other clinical trials and received related investigated drugs within 28 days prior to the first dose of study drug (counted from the date of the last treatment in the previous clinical trial, patients participated in the overall survival follow-up of the previous clinical trial can be accepted)
\. Patients should be excluded if they have a positive test for human immunodeficiency virus antibody (HIV-Ab) or treponema pallidum antibody (TP-Ab). Patients with positive Hepatitis B virus surface antigen (HBsAg) and/or hepatitis B virus core antibody (HBcAb) as well quantitative HBV-DNA above upper limit of normal value, and patients with positive hepatitis C virus antibody (HCV-Ab) as well quantitative HCV-RNA above upper limit of normal value, should also be excluded
\. Pregnant or lactating women; Or the blood pregnancy test of women at child-bearing age is positive during screening
\. Other conditions that may increase the risk of drug use in the study, or interfere with the interpretation of the study results, or affect the compliance of the study, etc
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note